Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS builds senior staff

Executive Summary

HHS Deputy Assistant Secretary for Public Health Emergency Preparedness William Raub will serve as Acting Counselor for Science Policy. Raub will be a senior policy advisor to Secretary Michael Leavitt, with responsibilities including FDA issues. He formerly sat on HHS' drug importation task force, which said the practice would be costly, risky and harmful to innovation (1"The Pink Sheet" Jan. 3, 2005, p. 28). Assistant Secretary for Legislation Jennifer Young will serve as Acting Senior Counselor for Health Policy, a new position. Young will advise Leavitt on health care issues including Medicare and Medicaid...

You may also be interested in...



Canada-Only Import Plan “Feasible,” HHS Says: Savings Would Be “Modest”

The Bush Administration would accept a Canada-only importation program that focuses solely on high volume brands, HHS Secretary Thompson and Commerce Secretary Donald Evans indicated in a Dec. 21 letter to Congress

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel